Business, energy, technology, markets and global industry news from Business News Today

ASCO 2026

PharmaDeviceNews ASCO 2026
Representative image of oncology researchers reviewing tumor imaging and clinical trial data, reflecting Immunome’s Phase 3 RINGSIDE results for varegacestat in adults with progressing desmoid tumors.
Pharma & Biotech

Why Immunome’s RINGSIDE data may reset expectations in desmoid tumor treatment

Discover how Immunome’s Phase 3 RINGSIDE data could reshape desmoid tumor treatment and gamma secretase inhibitor competition.

Read More
Representative image of oncology researchers studying tumor biology in a modern laboratory, reflecting Exelixis’ CABINET trial data on CABOMETYX and its potential role in advanced neuroendocrine tumor treatment.
Pharma & Biotech

Can Exelixis defend its oncology franchise with deeper CABINET evidence?

Read how Exelixis’ CABINET subgroup data could sharpen cabozantinib’s role in advanced neuroendocrine tumor care.

Read More
Representative image of an oncologist and clinical care team reviewing AI-powered cancer trial data, reflecting Massive Bio’s Reticulum Nexus push to improve oncology trial matching, biomarker reassessment and patient access after its ASCO 2026 product suite announcement.
Pharma & Biotech

How Massive Bio’s Reticulum Nexus suite is targeting the hidden bottlenecks in cancer trials

Can Massive Bio’s Reticulum Nexus suite close oncology trial access gaps? Find out how AI agents may reshape cancer trial navigation today!

Read More
Representative image: An oncologist reviews lung scan and precision medicine data, reflecting how Rybrevant plus Lazcluze could reshape first-line treatment expectations for atypical EGFR-mutated non-small cell lung cancer.
Pharma & Biotech

Is atypical EGFR-mutated NSCLC becoming Johnson & Johnson’s next precision oncology battleground?

Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.

Read More
Representative image showing a modern breast cancer consultation as Menarini’s elacestrant and capivasertib data raise fresh questions about oral targeted therapy in metastatic disease.
Pharma & Biotech

Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations

Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?

Read More
Representative image of oncology researchers reviewing lung cancer imaging and genomic data, reflecting Kelun-Biotech’s lunbotinib fumarate Phase II results in RET fusion-positive non-small cell lung cancer.
Pharma & Biotech

Kelun-Biotech’s ASCO 2026 data strengthens China’s next wave of targeted cancer drugs

Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.

Read More
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More
Representative image of advanced breast cancer research, reflecting Menarini Group’s ASCO 2026 elacestrant data and the growing focus on targeted treatment combinations for ER-positive, HER2-negative metastatic breast cancer.
Pharma & Biotech

ASCO 2026: Menarini’s elacestrant program expands the fight against endocrine resistance

Find out how Menarini’s elacestrant data at ASCO 2026 could reshape ER-positive metastatic breast cancer treatment.

Read More
Representative image of a cancer care specialist reviewing gastroesophageal scan data as BeOne Medicines’ HER2-positive gastroesophageal cancer results draw attention after ASCO 2026.
Pharma & Biotech

Could BeOne’s zanidatamab regimen reset expectations in HER2-positive gastroesophageal cancer?

Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.

Read More